Evaluation of the immunomodulatory effects of therapy with Brentuximab (IMMBRE)

Study type

• Study topic:
  Human medicinal product

  Disease /health condition
• Study type:
  Non-interventional study
• Scope of the study:
  Other
• If ‘other’, further details on the scope of the study:
  Evaluation of CD30 as a marker of immunosuppressive cells
• Data collection methods:
  Primary data collection

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Name of medicine:
  ADCETRIS
• Medical condition to be studied:
  T-cell lymphoma

  Hodgkin's disease stage I

  Hodgkin's disease stage II

  Hodgkin's disease stage III

  Hodgkin's disease stage IV

Population studied

• Short description of the study population:
  Adult patients with lymphoma treated with Brentuximab.
• Age groups:
  Adults (18 to < 46 years)

  Adults (46 to < 65 years)

  Adults (65 to < 75 years)

  Adults (75 to < 85 years)

  Adults (85 years and over)
• Special population of interest:
  Other
• Special population of interest, other:
  Lymphoma patients
• Estimated number of subjects:
  30

Study design details

• Main study objective:
  Evaluation of CD30 as a marker of immunosuppressive cells by analysis of the potential immunomodulatory effect of treatment with Brentuximab in patients with lymphoma
• Data analysis plan:
  Evaluation of CD30 as a marker of immunosuppressive cells by analysis of the potential immunomodulatory effect of treatment with Brentuximab in patients with lymphoma